![]() ![]() While the DOAC agents have demonstrated similar or a statistically reduced risk for major bleeding compared with warfarin in clinical trials for treatment of nonvalvular atrial fibrillation and venous thromboembolism, bleeding remains a concern with all anticoagulants. The approval of the first reversal agent in the US for a direct oral anticoagulant (DOAC) propels the evolution of patient care for those who require anticoagulation. The use of anticoagulants that directly affect thrombin, or the clotting factor Xa, has become mainstream practice over the past few years, often replacing warfarin as first-line therapy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |